Real-world epidemiology, treatment patterns and survival of multiple myeloma patients in a large nationwide health plan

Abstract

BackgroundSurvival of patients with multiple myeloma (MM) has improved significantly with access to autologous stem cell transplant (SCT) and new treatments. This study aims to describe epidemiology, treatment patterns, and outcomes of MM in Israel. MethodsA retrospective observational study was conducted in Maccabi Healthcare Services, a 2-million-member nationwide health plan in Israel. MM was defined by cross-linking data on MM diagnoses, dispensed treatments, and serum free light-chain assays. Point prevalence (31/12/2016) and incidence (2012–2016) rates were age-standardized. Newly diagnosed and treated patients (2009–2015) were followed through 31/12/2016 for progression to second-line (L2), with death as a competing risk. ResultsMM prevalence and incidence rates were 26.2 and 4.6 per 100,000 population, respectively. In the treatment cohort (N = 552), mean ± SD) age was 65.6 ± 11.3) years (60.1% male) and median (95% CI) OS in years was 5.2 (4.3–6.1) overall and 6.5 (4.9–8.1) for first-line (L1) bortezomib (N = 421). In a multivariable analysis, OS was significantly higher among patients starting L1 in 2012–2015 vs. 2009–2011. Within a year, 38.4% underwent SCT. Cumulative incidence of L2 was 38.2% and 51.4% within 1 and 2 years, respectively, and was associated with older age (≥65y; P < 0.001). ConclusionThese results from a large heterogeneous population demonstrate MM incidence and survival rates that are in line with the literature, together with a significant improvement in overall survival over time. Approximately half of newly treated patients progressed to L2 within two years. These results will serve as a baseline for further research to evaluate the clinical impact of new interventions.